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ABSTRACT: A supercritical antisolvent (SAS) process for obtaining zidovudine–poly(L-lactic acid) (PLLA) solid dispersions (SDs) was used
to attain a better intestinal permeation of this drug. A 32 factorial design was used, having as independent variables the ratio 3′-azido-2′3′-
dideoxythymidine (AZT)–PLLA and temperature/pressure conditions, as dependent variables the process yield and particle macroscopic
morphology. AZT–PLLA production batches were carried out by the SAS process, and the resulting products evaluated via scanning
electron microscope, X-ray diffraction, differential scanning calorimetry, and Fourier transform infrared analyses. From the nine possible
combinations of tests performed experimentally, only one combination did not produced a solid. The L3 batch of SD, produced with 1:2
(AZT–PLLA) ratio, resulted in a 91.54% yield, with 40% AZT content. Intestinal permeability studies using the AZT–PLLA from L3 batch
led to an AZT permeability of approximately 9.87%, which was higher than that of pure AZT (3.84%). AZT remained in crystalline form,
whereas PLLA remained in semicrystalline form. AZT release is controlled by a diffusion mechanism. It has been demonstrated that it is
possible to use PLLA carrier and SAS process to obtain SD, in a single step. C© 2015 Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci 104:1691–1700, 2015
Keywords: supercritical antisolvent process; supercritical fluids; zidovudine; poly(L-lactic acid); solid dispersion; oral absorption; gas-
trointestinal transit; everted rat intestinal sacs; permeability
INTRODUCTION
The treatment of Acquired Immune Deficiency Syndrome
(AIDS) is a public health problem throughout the world. Con-
ventional dosage forms have contributed to improve both the
quality of life and life expectancy of patients infected by the
Human Immunodeficiency Virus,1 but numerous factors still
hinder the best use of the available therapeutic arsenal.2,3 The
zidovudine (3′-azido-2′3′-dideoxythymidine; AZT) antiretrovi-
ral activity was first observed by Mitsuya et al.,4 being licensed
in the United States of America in 1986 for the treatment of
advanced HIV infection. In 1987, the use of AZT was expanded
in an open clinical study involving patients with AIDS and/or
those with HIV infection at high risk for developing AIDS; how-
ever, this clinical study received a notice of compliance in 1990.5
In the Biopharmaceutics Classification System,6 AZT (clog P
0.043999 and solubility of 10 mg/mL, pKa 9.8) is in the low-
permeability and high-solubility drugs group (class III).
The poly(L-lactic acid) (PLLA) is an aliphatic polyester that
degrades into L-lactic acid, a natural metabolic product. PLLA
is a semicrystalline aliphatic polyester with a melting point
in the range of 175°C–185°C, glass transition temperature in
the range of 60°C–65°C and molecular weight in the range of
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5000–700,000 Da.7,8 Aliphatic polyesters are used as biocom-
patible and biodegradable polymers for implantable controlled-
release systems (including rods, cylinders, tubes, films, fibers,
beads, and balls) and injection systems (including microcap-
sules, microspheres, and nanoparticles) for drugs of human and
veterinary use. The rate of biodegradation and drug release
characteristics from these controlled-release systems made of
aliphatic polyesters can be controlled by altering the physico-
chemical properties of the polymers, such as crystallinity, hy-
drophobicity, monomer stereochemistry, copolymer ratio, and
polymer molecular weight.7,8
Among controlled drug delivery systems, one can find sys-
tems such as polymeric solid dispersions (SDs), nanoparti-
cles, solid lipid nanoparticles, liposomes, nanoemulsions, den-
drimers, conjugated drugs, and hollow microspheres.
The established generation systems, either in micro- or
nanoscale, using conventional methodologies such as copre-
cipitation, coacervation, and solvent evaporation polymeriza-
tion, use large amounts of organic solvents and/or surfac-
tants that in general are harmful to the environment.9,10
The aforementioned methods used to produce particles com-
monly exhibit low rates of drug entrapment and difficulties in
scaling, and most often require further treatment for particle
removal from the solvent and/or impurities. Although the phar-
maceutical industry shows interest in innovative technologies
involving production of microparticles and nanoparticles, dis-
posal of solvents strongly limits the industrial production and
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generates increased costs.11 Hence, continued efforts to develop
other technologies that minimize the problems related to pol-
lution, toxicity, and ease of production scale-up has been the
subject of several studies.12–15
In the processes to achieve these goals, the supercritical
fluid (SCF) technology occupies a prominent role. The major
advantages of the SCF process are the simplicity of production
steps, the low temperature used in the process, and the use
of CO2.16 The supercritical antisolvent (SAS) process is based
on the decrease of solvent power of a polar organic solvent,
in which the substrate of interest (a pharmaceutical-active in-
gredient and/or polymer) is dissolved.17 Subsequently, this sat-
urated solution undergoes a SCF process to cause precipita-
tion and recrystallization of the substrate of interest. Hence,
the SCF is used to extract the solvent from this saturated
solution.11,15 The SAS process is easily scaled-up and has been
widely studied because of its potential in the production of mi-
croparticles and nanoparticles with controlled particles sizes
and morphology.18–20 The SAS process is usually carried out at
temperatures ranging from 35°C to 60°C, and is particularly
useful when thermolabile compounds need to be micronized.21
Sekiguchi and Obi22 first introduced the term SD, which
refers to the dispersion of one or more active ingredients in an
inert carrier in a solid state, frequently prepared by themelting
method, solvent method, or melting solvent method. SDs are
often used to increase the equilibrium solubility of poorly sol-
uble drugs in water,23,24 and SDs prepared with poorly soluble
carriers have been used to control the dissolution rate of water-
soluble drugs, with the aim of obtaining controlled-release sys-
tems. The PLLA is a copolymer semicrystalline, slightly soluble
in water and used in modified drug delivery systems.
It has been demonstrated in this research effort that it is
possible to use PLLA as a carrier for preparing AZT SD to
control the drug dissolution rate and SAS process to obtain SD,
so as to attain a better intestinal absorption of the AZT.
MATERIAL AND METHODS
Chemicals
3′-Azido-2′3′-dideoxythymidine was kindly provided by
Cristalia (lot 0035/13, purity grade 99.849%; Itapira, Sa˜o
Paulo, Brazil). PLLA was manufactured by the Biomaterials
Research Group of the Faculty of Medical and Health Sciences
at PUC-SP and kindly provided by Prof. Eliana Aparecida
de Rezende Duek. The TC199 tissue culture medium was
composed of 8.47 g NaCl, 0.34 g KCl, 0.126 g CaCl2·2H2O,
0.595 g NaHPO4, and 0.018 g glucose, to prepare 1 L of solution
with pH 7.4. All other chemicals used were of reagent or
pharmaceutical grade.
Analytical and Processing Equipment
The SCF system utilized for this research work was from Wa-
ters Corporation (SAS-RESS Combined System, Pittsburgh,
Pennsylvania). For dissolution and the removal of the dis-
persed gas in solution was used bath ultrasound (Unique
USC2800A; Indaiatuba, Brazil). All spectrophotometric read-
ings were carried out in a UV–Vis spectrophotometer from Shi-
madzu (MultiSpec-1501; Kyoto, Japan). All dissolution tests
were carried out using a dissolution apparatus from Amer-
ican Lab (AL1000; Charqueada, Brazil). Scanning electron
microscopy analyses were carried out in a scanning electron
microscope (SEM) from Leica (Leo 440i; Cambridge, England),
following gold sputter coating of the particles with a Sputter-
Coating plating device also from Leica (SC7620). All infrared
spectrophotometric analyseswere performed in aFourier trans-
form infrared (FTIR) spectrophotometer fromThermoScientific
(Nicolet 6700; Madison, Wisconsin) with Fourier transform,
coupled with an Omni Smart-Sampler also from Thermo Scien-
tific. All differential scanning calorimetry (DSC) analyses were
carried out in a Differential Scanning Calorimeter from Shi-
madzu (DSC-60), equipped with an accessory flow-controller
(60A) and an interface for data acquisition and control (TA-
60WS) also from Shimadzu. X-ray powder diffraction analyses
were carried out in X-ray diffractometer fromPhilips Analytical
(X’Pert-MPD; Almelo, The Netherlands).
EXPERIMENTAL PROCEDURES
Experimental Design
To reduce the number of runs needed to obtain the highest
amount of information on product performance, the screening
was planned using an experimental (factorial) design. Specif-
ically, a randomized plan was employed, as two factors were
evaluated each at three levels, and experimental trials were
performed with all nine possible combinations. A 32 factorial
design was thus used, producing nine runs. In the present re-
search effort, the ratio of AZT–PLLA (X1) and the conditions
of temperature and pressure (X2) were selected as independent
variables. Mixtures of AZT–PLLA were evaluated at ratios of
2:1, 1:1, and 1:2, whereas the temperature/pressure of the pro-
cess was evaluated at 45°C/85 bar, 45 °C/100 bar, and 45°C/135
bar.
Preparation of Production Batches
The AZT–PLLA solution was prepared at 15% (w/v) by dis-
solving of AZT in 5 mL of ethanol and PLLA in 95 mL of
dichloromethane, and then the solution of AZT was mixed
with the solution of PLLA. A bath with ultrasound (frequency
40 kHz, 30°C/30min) was used to remove any gases and homog-
enize the AZT–PLLA solutions. The schematic representation
of the SAS process is depicted in Figure 1. During the produc-
tion trials, the temperature was maintained at 45°C and the
pressure of the systemwas varied at 85, 100, and 135 bar.When
steady-state conditions were reached in the high-pressure ves-
sel (V1; see Fig. 1), the AZT–PLLA solution was released into
V1 chamber by a high-pressure pump (P2; see Fig. 1) at a flow
rate of 0.75 mL/min and further sprayed through a stainless
steel capillary tube (101.6 :m internal diameter). The spray-
ing was maintained for 27 min, followed by another 20 min
of CO2 spraying supplied at a rate of 3.0 mL/min to remove
any residual organic solvent. When the cleaning step was com-
pleted, the high-pressure vessel (V1) was slowly depressurized
and product samples were collected for full physicochemical
characterization.
AZT Loading and AZT Loading Efficiency
To determine the free drug mass or just adsorbed to the parti-
cle surface, an analytically weighed mass of the samples (L3,
L5, and L9) was dispersed in 50 mL of purified water (pH 7)
and stirred for 15 min in an ultrasound bath (40 kHz) and fil-
tered under vacuum. The concentration of AZT in the filtrate
was determined by UV spectroscopy (266 nm). Samples were
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Figure 1. Schematic representation of the SAS process.
transferred to a volumetric flask and diluted with purified wa-
ter (pH 7) to 100 mL and maintained for 60 min in ultrasound
bath (40 kHz), 65°C. The dispersion was filtered and AZT con-
centration was determined by UV spectroscopy (266 nm). The
drug loading of SD was expressed as the mass fraction of en-
capsulated drug relative to the mass of the sample, and was
calculated using the following equation:
Drug loading (%) =Mass of encapsulated drug
Totalmass of particle
× 100 (1)
The drug loading efficiency was then determined as:
Drug loading efficiency (%) = Drug loading (%,w/w)
Theoretical drug loading (%,w/w)
× 100 (2)
Dissolution Test
The release rate profile of AZT from the product samples (30mg
of each sample was weighed analytically) was examined in vitro
at predetermined time, using a USP II dissolution apparatus.
The dissolution medium contained 900 mL of simulated gastric
fluid, without pepsin, at pH 1.2, with the temperature main-
tained at 37 ± 0.5°C. At predetermined time intervals, 5 mL
samples were withdrawn and duly filtered. The volume of the
dissolution medium was kept constant by means of immediate
reposition following sample withdrawal. The test was carried
out under sink conditions, and the concentration of AZT dis-
solved in the medium was then determined via spectrophoto-
metric readings at 266 nm, as described above.
Kinetic Modeling of Drug Dissolution
Three mathematical models for interpreting dissolution kinet-
ics were fitted to the AZT release data gathered from the dis-
solution tests, using the software SigmaPlot
TM 10.0. The equa-
tions ln Qt = ln Q0K1t, Qt = Q0 + KHt1/2 and Qt/Q = KKPtn
were used to test the models of the first order, Higuchi, and
Korsmeyer–Peppas, respectively. In these models, Qt is the
amount of drug dissolved at any time t,Q0 is the initial amount
of drug in the solution, K1 is a first-order release constant, KH
is a Higuchi dissolution constant trend, KKP is a constant in-
corporating structural and geometric characteristic of the drug
dosage form, and n is a release exponent.25
Scanning Electron Microscopy Analyses
Particles were analyzed for morphological characteristics using
a SEM and a Sputter Coater. Briefly, samples for SEM analy-
sis were prepared by lightly sprinkling the powdered particles
on an adhesive double-face tape kept adhered on an aluminum
stub. Samples were then sputter-coated with gold to a thick-
ness of about 300 A˚, under inert (argon) atmosphere with high-
vacuum evaporator. Samples were randomly scanned, photomi-
crographed at 5 kV, and magnified at 50× up to 3000×.
Analyses via Infrared Spectrophotometry with Fourier Transform
The infrared spectra of AZT, PLLA, and SDs were gathered
in the range of wavenumber from 4000 to 675 cm−1 with a
resolution of 4 cm−1, using an infrared spectrophotometer with
Fourier transform. FTIR spectra were obtained in ATR mode,
using the accessory Omni Smart-Sampler (Thermo Scientific).
DSC Analyses
All samples were subjected to analyses in a Differential Scan-
ning Calorimeter, equipped with an accessory flow-controller, a
software, and dedicated interface for data acquisition and con-
trol. Samples weighing approximately 2 mg were placed inside
aluminum pans, duly sealed using a crucible, and subject to a
heating cycle from 30°C to 350°C at a constant heating rate of
10°C/min under inert (nitrogen) atmosphere.
X-ray Diffraction Analyses
X-ray diffractograms of samples of AZT, PLLA, and SDs were
obtained in a X-ray diffractometer using filtered Ni and Cu
K" radiation (Cu K" of 8 = 1.54060 A˚). Analyses were per-
formed at a diffraction angle of 22 (from 4° to 40°, step: 0.02°,
speed 0.05°/s) with voltage and current set at 40 kV and 40 pA,
respectively.
DOI 10.1002/jps.24377 Yoshida et al., JOURNAL OF PHARMACEUTICAL SCIENCES 104:1691–1700, 2015
1694 RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology
In Vitro Intestinal Permeation Studies Using Everted Rat Intestinal
Sacs
3′-Azido-2′3′-dideoxythymidine intestinal permeation was eval-
uated in vitro using the everted rat intestinal sac (ERIS) model.
The ERIS was obtained from adult male Wistar rats, weighing
from 250 to 300 g and fasted for a period of 8 h. This period
of fasting was established according to the scientific literature
related to the investigation of permeability of substances using
the proposed in vitro model.23,26,27 Rats were anesthetized us-
ing halothane solution and pentobarbital (intraperitoneal anes-
thetic 0.5 mg/Kg) and the small intestine was immediately dis-
sected, washed with TC199 medium previously kept at 10°C,
and submerged in 20 mL of oxygenated (O2–CO2 ratio of 95:5)
TC199 tissue culture medium at the same temperature. The
intestine was then everted using a flexible rod with its end
protected by a thin silk fabric (mini brush); one extremity was
closed using suture thread, and the intestinal segment filled
with TC199 solution. The intestinal segment (6 cm) was lig-
ated at one end, and was closed at the other end. The incubation
medium was added of the unprocessed AZT, AZT–PLLA SD, or
AZT–PLLA physical mixture, respectively, 5, 6, and 6 mg. Incu-
bation of the closed ERIS was carried out at 37°C under gentle
agitation. After an incubation time of 60 min, samples (n= 6) of
both the inner fluid (in contact with the serousmembrane of the
ERIS) and outer fluid (in contact with the mucous membrane
of the ERIS) were filtered and analyzed by UV–Vis spectropho-
tometry at a wavelength of 266 nm. After collecting the data,
values of the samples were analyzed by using unpaired Stu-
dent’s t-test, at the 0.05 level, using OriginPro 8 (OriginLab R©)
software.
The protocol for the study of intestinal drug permeation
using ERIS was duly approved by the Ethics Committee on
Animal Use (CEUA) of the Federal University of Sa˜o Carlos
(UFSCAR), under No. 003/2011, catering to CFMV Res No.
1000/2012.
RESULTS
Selection of Processing Parameters for Preparation of SDs Under
Supercritical Conditions
Results of both yield (%) and appearance of SDs of AZT with
PLLA are displayed in Table 1. Batches of L1 through L9 cor-
respond to the formulations obtained via the 32 experimental
factorial design. The independent variable X1 (in three differ-
ent levels, viz., +1, 0, and −1) and the independent variable X2
(also in three different levels, viz.,+1, 0, and−1) resulted in the
production of different solid precipitate aspects, except for L1.
The results obtained guided the selection of samples for further
physicochemical analyses. With respect to yield and appear-
ance of the product, the L3 SD (91.54% yield, solid particulate
with uniform appearance) was selected for both physicochemi-
cal characterization and ex vivo study of intestinal permeation.
Additionally, considering the same dependent variables, SDs
L5 (59.06% yield, solid particulate with filamentous nonuni-
form aspect) and L9 (51.50% yield, solid particulate with fil-
amentous nonuniform aspect) were also selected. Formulation
L3 corresponds to a ratio of AZT–PLLA of 1:2 (level +1) and
temperature of 45°C and pressure of 85 bar (level −1). This for-
mulation displayed a high degree of uniformity and was free of
lumps. The other formulations selected (L5 and L9) exhibited
a varying degree of uniformity and presented large lumps.
Table 1. Experimental Results of 32 Factorial Design
Coded Values
Batch X1 X2 Yield Appearance
Code (AZT–PLLA) (T,P) (%) of Product
L1 +1 +1 0 -
L2 +1 0 51.50 +++
L3 +1 −1 91.54 +
L4 0 +1 78.74 +++
L5 0 0 59.06 ++
L6 0 −1 75.80 +++
L7 −1 +1 77.29 +++
L8 −1 0 62.50 +++
L9 −1 −1 51.50 ++
Coded values X1 X2
−1 2:1 45°C, 85 bar
0 1:1 45°C, 100 bar
+1 1:2 45°C, 135 bar
-, Product not obtained; +, solid particles of uniform aspect; ++, solid partic-
ulate of filamentous and nonuniform aspect; +++, nonparticulate solids.
Scanning Electron Microscopy Analyses
Results from SEM analyses can be found in Figure 2. The mi-
crographs of AZT and PLLA unprocessed with magnification of
400× (Figs. 2a and 2b) show the crystalline form of the drug28,29
and polymer filamentous form of the polymer. Figures 2c and
2d (L3) show significant reduction in size and diameter of the
PLLA fibers and size of the AZT crystals. Both the L5 (Fig. 2e)
and L9 (Fig. 2f) formulations exhibited a disorganized morphol-
ogy when compared with L3.
DSC Analyses
Results from the DSC analyses of pure AZT, PLLA, and SD
formulations (viz., L3, L5, and L9) are displayed in Figure 3.
As can be observed from a close inspection of Figure 3, the
thermogram of pure AZT exhibited an endothermic peak in the
temperature range between 120°C and 130°C, corresponding
to the melting point of AZT crystals (Tonset = 123°C, with an
enthalpy of absorption of 100.6 J/g), which is in close agreement
with the data described in the scientific literature.28–30
Regarding the PLLA (a semicrystalline polymer) thermo-
gram (see Fig. 3), a Tonset of 167°C was produced, which is con-
sistent with the melting temperature range of 165°C–185°C
described in the literature.31 This same event was observed,
but at a much lower intensity, in the thermograms of the SD
formulations produced, viz., L3, L5, and L9. The energy ab-
sorbed (melting enthalpy) by AZT and PLLA (viz., HAZT and
HPLLA, respectively) was calculated as the ratio of the value of
integral (U, mJ) produced to the sample weight (mg), for each
microcalorimetric assay. The experimental melting enthalpies
(Hobserved) together with the theoretical values for the melt-
ing enthalpies (Htheoretical) calculated for the L3, L5, and L9
formulations are displayed in Table 2. Being that the values of
Htheoretical (J/g) was calculated by Eq. (3).
Htheoretical = mAZTinsample × HAZTmsample (3)
The experimental values for the melting enthalpies were
higher than the theoretical ones for all the SD formulations
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Figure 2. Scanning electron microphotographs of unprocessed AZT (a: ×400), unprocessed PLLA (b: ×400), L3 formulation (c: 400×; d: 3000×),
L5 formulation (e: 3000×), and L9 formulation (f: 3000×).
Figure 3. Normalized DSC thermograms of pure AZT, PLLA, and of L3, L5, and L9 SD systems.
Table 2. Results of both Theoretical Calculated and Observed
Experimental Values for the Melting Enthalpies of all SD
Formulations Assayed
Melting Enthalpy
SD Hobserved Htheoretical (H)
Formulation (J/g) (J/g) (J/g)
L3 72.875 63.089 9.786
L5 91.720 40.432 51.288
L9 22.729 9.453 11.276
tested (see Table 2), especially in the case of SD L5 [Hcalculated
= 40.4 J/g;(H) = 51.3 J/g], showing that there was a greater
demand of energy to break the intermolecular bonds than that
theoretically predicted.
X-ray Diffraction Analyses
X-ray diffraction (XRD) analytical techniques are especially
significant for the analysis of solid materials. The decisive
advantage of XRD methods over other analytical techniques
is based on the unique character of the diffraction patterns
of crystalline substances, the ability to distinguish between
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Figure 4. Normalized X-ray diffractograms for pure AZT, PLLA, and
the SD systems produced (viz., L3, L5, and L9).
elements and their oxides, and the possibility to identify chem-
ical compounds, polymorphic forms, and mixed crystals by a
nondestructive examination. Hence, the crystalline state of
AZT in the SD formulations was confirmed by XRD analyses.
The results obtained in the XRD analysis, performed to pure
AZT, PLLA, and to the three SD formulations, are displayed in
Figure 4 in normalized intensity fashion.
As the intensity of the peaks in the diffraction patterns
also depends on the drug concentration, a decrease in the
size of peaks was expected for the SD systems encompass-
ing lower AZT–PLLA ratios. The X-ray diffractogram of pure
AZT indicates the crystalline structure of the drug, whereas
the diffractograms of the SD systems clearly present the same
pattern. Normalization of the intensity values in all X-ray
diffractograms was made by dividing the diffractograms by the
highest peak value in each diffraction pattern, thus allowing a
better comparison between all X-ray diffractograms. The AZT
diffractogram exhibited several peaks, indicating that it is a
crystalline solid. Regarding PLLA, its diffractogram exhibited
a wide background, characteristic of an amorphous compound
(without fine-tuned baseline and well-defined peaks), except in
the range of 16.04 22 17.02, where the small peaks produced
indicate the crystalline residues of PLLA, thus allowing one to
characterize this compound as a glassy amorphous polymer,8
an interpretation that is reinforced by the presence of similar
small peaks in all the SD systems analyzed. The maintenance
of AZT crystalline state in L3, L5, and L9 SD systems can be
clearly observed in the diffractograms of those SD systems (see
Fig. 4), which show sharp peaks related to AZT in the broad-
band referring to PLLA.
Analysis by Fourier Transform Infrared Spectroscopy
Results obtained in the FTIR analyses performed to pure
AZT, PLLA, and SD systems L3, L5, and L9, are displayed in
Figure 5.
As can be observed from a close inspection of Figure 5, the
FTIR spectra of pure AZT and of the SD systems (L3, L5, and
L9) all exhibit the characteristic stretching bands of the CO at
1683 cm−1 and of the azide group at 2083 cm−1. One stretching
band at 1380 cm−1 can be attributed to CH2 and one stretching
Figure 5. Fourier transform infrared spectra of pure AZT, PLLA, and
the SD systems produced (viz., L3, L5, and L9).
Table 3. Drug Load and Encapsulation Efficiency of the AZT SD L3,
L5, and L9
Theoretical AZT AZT AZT AZT
AZT Loading Content Free Loading Efficiency
SD (%, w/w) (:g/mL) (:g/mL) (%) (%)
L3 33 6.97 4.41 13.1 39.8
L5 50 13.42 1.07 23.0 46.0
L9 67 5.12 0.05 7.0 10.4
at 1281 cm−1 can be assigned to C–O–C and C–OH groupings.
The intervals of the stretching bands produced in the research
effort described herein were similar to those obtained by Arau´jo
et al.30 and Fu et al.,32 and indicate the stable nature of AZT
during the production process of the SD systems.
It can be seen in Figure 5 that the L3, L5, and L9 samples
show the same bands as the PLLA: stretching of the CO at
1750–1760 cm−1 and peaks in the 1080–1100 cm−1 region cor-
responding to C–O stretching. The peaks at 1380 and 1450 cm−1
were assigned to CH3 and CH bending. More detailed frequen-
cies and their corresponding vibrational modes can be found in
the work of Garlotta.33 The crystalline and amorphous phases
were present in the PLLA and supercritical processed samples.
This fact was corroborated by XRD.
AZT Loading in L3, L5, and L9 Systems
Results obtained for the AZT loading efficiency following deter-
minations of AZT in the SD systems produced are showed in
Table 3. The AZT in the samples evidenced that the drug was
preserved during the SAS process. Among the samples investi-
gated, L5 SD showed higher drug content.
In Vitro Release Behavior of AZT
The release of AZT from the L3, L5, and L9 SD systems was
evaluated at pH 1.2, as shown in Figure 6, and could be de-
scribed by amodified release profile. The L3 SD system released
86% of the AZT at 24 h, whereas L5 SD system released only
approximately 76% AZT over 24 h and L9 SD system released
almost 100% over 6 h. The difference in release profiles among
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Figure 6. Release profile of AZT from the SD systems produced.
the three samples is related to the encapsulation efficiency and
the degradation of PLLA. The release profile of the samples
L3, L5, and L9 (Fig. 6) corresponds to the free AZT rate or
adsorbed to the surface of the polymer (Table 3). The release
of AZT from the SD systems is directly related to the stages
of PLLA degradation. According to Severino et al.,34 PLLA,
being an aliphatic polyester, is degraded in four consecutive
steps: hydration, initial degradation, subsequent degradation,
and solubilization. During the PLLA hydration stage, the aque-
ousmediumwithin which the polymer is submerged penetrates
in the polymeric matrix, producing a relaxation of the polymer
fibers and leading to a decrease of the glass transition temper-
ature. The initial degradation of PLLA begins in the hydrated
polymer via hydrolysis of the ester linkages, resulting in the
cleavage of the polymer main chain, releasing lactic acid, and
thus promoting a reduction of PLLA molecular weight. The
hydrolysis reaction continues inside the hydrated polymer ma-
trix in such a way that the molecular weight of the polymer
continuously decreases while maintaining its integrity. During
the subsequent degradation of the polymer chain, its molecular
weight decreases to a point where the polymer cannot continue
to maintain its integrity, and thus the polymer starts to loose
mass because of solubilization in the aqueous medium. In the
Biopharmaceutical Classification System,6 AZT is character-
ized by being highly soluble and, although dispersed in the SD
systems, it was fully solubilized following PLLA hydration and
subsequent degradation stages.
In Vitro AZT Release Kinetics
The dissolution pattern of AZT was successfully modeled ac-
cording to three models, that is, first-order, Higuchi, and
Korsmeyer–Peppas kinetic models, and duly compared in or-
der to evaluate the release kinetics.25 Results obtained are dis-
played in Table 4. The first-order kinetic model describes the
dissolution of a drug from dosage forms such as those contain-
ing water-soluble drugs in porous matrixes.25 In this model,
for each SD system, the natural logarithm of dissolved amount
of AZT in the immediately preceding time was plotted versus
time. The Higuchi model describes the dissolution of a drug
from various types of modified-release dosage forms, such as in
Table 4. Results from the Nonlinear Fittings of the Three Kinetic
Models to the Dissolved Amount of Released AZT Produced by the
Different SD Systems L3, L5, and L9
Kinetic Model Fitted
First Order Higuchi Korsmeyer–Peppas
SD System K1 r KH r KKP n r
L3 0.031 0.857 3.966 0 39.297 0.139 0.996
L5 0.001 0.715 1.937 0.921 6.210 0.319 0.989
L9 0.022 0.974 4.035 0 38.606 0.146 0.949
the case of some patches and matrix tablets with incorporated
water-soluble drugs. In this model, for each SD system, the
square root of time was plotted against the dissolved amount
of AZT in the immediately preceding time. Korsmeyer et al.35
have developed a semiempirical simple model for describing
the exponential drug release in time, which describes the re-
lease of a drug from a polymeric model system. Later, Peppas36
used the exponent release value (n) to characterize different
release mechanisms, and concluded that the drug transport
mechanism can be classified as either a non-Fickian or Fickian
diffusion process.
The L3 SD system did not respond well to the Higuchi model,
and exhibited a low linearity producing an r value of 0.857 for
the first-order kinetic model (Table 4). However, both L3 and
L5 SD systems produced a good linearity in response to the
Korsmeyer–Peppas model. The n value for both L3 and L5 SD
systems was lower than 0.5 (Table 4), which was an indica-
tion that the drug diffusion through the polymer proceeded
according to a Fickian diffusion mechanism. Although the L5
SD system produced a release of approximately 76% AZT dur-
ing a timeframe of 24 h, it also produced r linearity for the
Higuchi model, reinforcing the suggestion that the release of
AZT proceeded as a diffusion mechanism based on Fick’s law
and, therefore, this model can be used to describe the disso-
lution of a drug according to a modified-release profile.25 The
L9 SD system drug release kinetics displayed linearity for the
first-order model, thus confirming the dissolution of AZT for re-
lease. However, for the L9 SD system, the r value obtained for
the Korsmeyer–Peppas model (0.949) was very similar to that
obtained for the first-order model (0.974), and if we consider n,
the Fickian diffusion is again suggested as a mechanism for the
transport of AZT (Table 4). On the basis of this analysis, we can
conclude that the release of AZT in the dissolution medium (pH
1.2 or 7.0) depends on the hydrolytic degradation of the PLLA
followed by diffusion of the drug.
Evaluation of Ex Vivo Intestinal Permeation
3′-Azido-2′3′-dideoxythymidine intestinal permeation was eval-
uated using the ERIS model and the results obtained are dis-
played in Figure 7. Tominimize the use of animals in the experi-
mental trials, the L3 SD systemwas selected because of both its
macroscopic characteristics (uniform particle aspect) and yield
(58.7%). Hence, the ex vivo intestinal permeation tests evalu-
ated only the L3 (AZT–PLLA) SD system, and the data gath-
ered from these trials were duly compared with the permeation
of unprocessed AZT and drug–polymer physical mixture. For
unpaired (two sample) t-test, the difference of the population
means—for both AZT concentration in internal media (AZTIM)
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Figure 7. Quantification of AZT, for unprocessed drug (AZT), AZT
from L3, and AZT from drug–polymer physical mixture (PM), in both
the ERIS internal and external medium (n = 6), following the in vitro
intestinal permeation studies.
and external media (AZTEM) for unprocessed AZT and AZT re-
leased for L3—is significantly (p < 0.05) different. The intesti-
nal permeation of AZT from the L3 SD system (9.87 ± 0.47%)
was higher than both the unprocessed AZT (3.84 ± 0.45%) and
AZT–PLLA physical mixture (5.40 ± 0.93%) in the ERIS inter-
nal environment (in contact with the serous membrane) (see
Fig. 7), hence suggesting that the SD system produced by us-
ing SCF processing significantly (p < 0.05) increased the rat
intestinal absorption of AZT.
DISCUSSION
In the SAS process, SC-CO2 is used as antisolvent. When the
droplets come into contact with the SC-CO2, a very rapid diffu-
sion phenomenon takes place, including phase separation and
solute precipitation.37 The solvent volume expansion reduces
the ability to promote solvation and liquid phase supersatura-
tion, with subsequent particle formation by drug precipitation
with the carrier.38
The characteristics of the solids dispersions can be attributed
to the proportion of AZT and PLLA, or to the conditions of su-
percritical pressure in the system environment, as the condi-
tions of temperature and CO2 flow were kept constant for all
formulations.
The AZT theoretical loading rate for the formulations L3,
L5, and L9 were, respectively, 33% (1:2), 50% (1:1), and 67%
(2:1). However, for lower drug theoretical rates, the incorpora-
tion was higher, 40% (L3), 46% (L5), and 10% (L9). This can
be attributed to precipitation of AZT during the SD formation,
whereas the PLLA remained in solution because of the higher
lipophilicity of the system, and did not coprecipitated with AZT
until the solubility limit was reached. When AZT–PLLA ra-
tio increased, the SC-CO2 was saturated with PLLA gradually
increasing the incorporation efficiency of AZT in SDs to more
than 40%, for L3 and L5 (Table 3). When AZT–PLLA ratio
decreased, saturation SC-CO2 was insufficient to promote co-
precipitation, decreasing the efficiency of incorporation of AZT,
for L9. The interpretation of these results is in agreement with
other studies.39,40 Bodmeier and McGinity41 reported that the
partitioning of substances into the external phase during par-
ticles formation is a problem commonly seen with technique
using immiscible phase.
The mass of components integrating the formulations
that was not recovered in the SDs may have been dis-
charged together with the solvent during its removal from
the vessel of precipitation (Fig. 1). The mass transfer be-
havior of the fluid droplets is regarded as a critical fac-
tor in the process, influencing yield, particle morphology,
and size. Dukhin et al.42,43 demonstrated the existence of
droplets in transient conditions slightly above the mixture
critical point, because of the existence of a dynamic interfa-
cial tension. Consequently, the description of mass transfer
from a single droplet, even under miscible conditions, appears
reasonable.
In SEM, figures can observe the change in the morphology
of both AZT and PLLA in the SD form and a rearrangement of
the polymer chains into smaller fractions and nanoparticles of
AZT onto the polymer surface.
Results obtained in this are in close agreement with those
described in the literature.29,44,45 Hence, results from both the
XRD and DSC analyses of the L3, L5, and L9 SD systems
strongly suggest that AZT is in crystalline form in those sys-
tems.
The aforementioned PLLA degradation stages, coupled with
the data produced in the study of the AZT release kinetics (see
Table 4), clearly indicates that AZT was solubilized during the
PLLA hydration stage, and further released from L3, L5, and
L9 SD systems by a diffusion mechanism during the initial
stages of PLLA degradation.
From SEM, observations are evident that the AZT par-
ticles increased in specific surface area, which may explain
the observed change in the dissolution rate. The molecular
diffusion of AZT through the polymer is an efficient, sim-
ple, and reliable means to achieve controlled-release of the
AZT. The SD is a reservoir type device that utilizes this phe-
nomenon. The main steps in the release of AZT from SDs
were diffusion into the reservoir, dissolving carrier fluid be-
tween the reservoir and the polymer membrane, diffusion
through the membrane, partition between membrane and elut-
ing fluid, and finally, transport away from the device surface.46
If the reservoir contains an excess of AZT, the concentra-
tion profile at steady state can be maintained. However, af-
ter depletion of the reservoir, the concentration profile will
change.
The absorption of AZT depends on its intrinsic characteris-
tics of both solubility and permeability (ability to diffuse across
the apical membrane of the lipophilic enterocytes, based on ap-
pearance of the drug in the serosal side and disappearance of
the drug from the mucosal side) in the aqueous environment of
the intestinal lumen. Results produced in this study are sup-
ported by the results of AZT release from the L3 SD system by
a modified-release pattern of the drug. AZT is recognized as a
BCS Class III drug6 with high solubility and low permeability.
Hence, in the present research effort, AZT absorption from the
L3 SD system was highly enhanced relative to its pure counter-
part and so AZT release from the aforementioned SD system
should be studied for a longer timeframe (>10 h) using the
ERIS model to generate more extensive data comparable to the
dissolution test data.
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CONCLUSIONS
The experimental results presented clearly demonstrate that
it is possible to produce modified drug release systems via a
SAS process for a BCS class III drug that is primarily absorbed
in the stomach and in the duodenum. Results obtained show
that the dissolution and absorption properties of AZT were en-
hanced as a consequence of PLLA degradation, and that the
AZT integrated in a SD system with PLLA allowed to modify
its in vitro release.
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